Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q07075

UPID:
AMPE_HUMAN

ALTERNATIVE NAMES:
Aminopeptidase A; Differentiation antigen gp160

ALTERNATIVE UPACC:
Q07075; Q504U2

BACKGROUND:
The protein Glutamyl aminopeptidase, recognized alternatively as Aminopeptidase A or Differentiation antigen gp160, is crucial in controlling central hypertension. It achieves this through a calcium-modulated mechanism, preferentially cleaving N-terminal acidic residues from vital peptides such as angiotensin II.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Glutamyl aminopeptidase offers a pathway to innovative therapeutic approaches. Given its significant role in the regulation of hypertension by modulating angiotensin II, targeting this protein could lead to breakthroughs in hypertension management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.